TG
RNAM

TCW Group’s Avidity Biosciences RNAM Stock Holding History

TCW Group’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-14,202
Closed -$310K – 356
2021
Q1 		$310K Sell
14,202
-168,879
-92% -$4.13M ﹤0.01% 324
2020
Q4 		$4.67M Buy
+183,081
New +$5.34M 0.04% 195

Other funds holding RNAM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

TCW Group's RNAM Position: Q2 2021 in Review

TCW Group sold out of Avidity Biosciences (RNAM) in Q2 2021, closing a stake of 14,202 shares — an estimated $310K sold.

TCW Group first reported a position in RNAM in Q4 2020 and held it in 2 quarters. The position peaked at $4.67M in Q4 2020. 95 funds tracked by Wall St. Rank hold RNAM as of Q2 2021.

  • TCW Group reported no remaining Avidity Biosciences position as of Q2 2021 after selling out during the quarter.
  • TCW Group sold 14,202 Avidity Biosciences shares in Q2 2021, an estimated $310K.
  • TCW Group first reported a position in Avidity Biosciences in Q4 2020 and held it in 2 quarters.
  • TCW Group's Avidity Biosciences position peaked at $4.67M in Q4 2020.
  • 95 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2021.

Based on TCW Group's 13F filing for Q2 2021, filed 23 Jul 2021.